drugset / Trial / NCT06732492
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Phase 1
Recruiting
10 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nanjing Bioheng Biotech Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer/T cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。
Timeline
- Start
- 2024-10-31
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RD13-02 | Cell therapy | — | Intravenous |